ArticleBMC cancer2025
New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveAcute myeloid leukemia (AML) is a malignant blood disease with a poor prognosis. With the development of targeted therapies, many refractory/relapsed or unfit AML patients have achieved better survival rates. However, primary or acquired resistance frequently occurs, and some targets become unavailable. This study aimed to identify and verify novel targets for AML using Mendelian Randomization (MR) analysis.
methodThe association between plasma protein quantitative trait loci (pQTL), expression quantitative trait loci (eQTL), and AML was examined via MR. Bayesian co-localization analysis was used to detect common segments of TCL1A and AML. Bioinformatics technology was used to explore the relationship between TCL1A and AML, and quantitative real-time PCR (RT-qPCR) analysis was used to detect the expression of TCL1A in various cell lines. Furthermore, high-throughput virtual screening (HTVS) and molecular dynamics (MD) simulation was used to identify potential TCL1A inhibitors. Further verification was carried out by AML cell experiments.
resultsOur study found a strong association between plasma TCL1A protein levels and AML (OR: 1.66; 95% CI: 1.46–1.88), and rs78986913 was the same variant in both TCL1A and AML. High TCL1A expression was associated with low overall survival rates in AML patients (P < 0.001), especially in the FAB M0 and M2 subgroups. Additionally, TCL1A was abnormally highly expressed in many AML cell lines (including MOLM-13, MV4-11, THP-1) compared to normal bone marrow stromal cells (HS-5) and other solid tumor cells. We also identified 19 small molecules, finding that Bletilloside A (id number: 2292159-89-6) is one of the most fitting small molecules for the TCL1A protein pocket. MD simulation confirmed the good stability of the Bletilloside A-TCL1A complex. And Bletilloside A could inhibit the proliferation of AML by inhibiting TCL1A.
conclusionThere is a causal relationship between TCL1A and AML. The expression level of TCL1A deserves further monitoring in clinical settings, and the benefits of targeting TCL1A should be further validated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.